Showing results (561-570 of 6,664) with videos related to

Sort By:
Pageof 667
Annals of Hematology|April 19, 2017
Impact of cachexia on outcomes in aggressive lymphomasReem Karmali, Taha Alrifai, Ibtihaj A M Fughhi, et al.
Annals of Hematology|November 13, 2016
MCM7 polymorphisms associated with the AML relapse and overall survivalJin Sol Lee, Hyun Sub Cheong, Youngil Koh, et al.
Annals of Hematology|October 25, 2016
Pre-engraftment bloodstream infections in acute leukemia patients undergoing unrelated cord blood transplantation following intensified myeloablative conditioning without ATGChangcheng Zheng, Baolin Tang, Xiaoyu Zhu, et al.
Annals of Hematology|November 1, 2016
Cognitive and fine motor deficits in a pediatric sickle cell disease cohort of mixed ethnic originLuise Burkhardt, Stephan Lobitz, Elisabeth Koustenis, et al.
Annals of Hematology|October 13, 2016
Myocardial and liver iron overload, assessed using T2* magnetic resonance imaging with an excel spreadsheet for post processing in Tunisian thalassemia major patientsMonia Ouederni, Monia Ben Khaled, Fethi Mellouli, et al.
Annals of Hematology|October 19, 2016
Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registryKitsada Wudhikarn, Udomsak Bunworasate, Jakrawadee Julamanee, et al.
Annals of Hematology|November 30, 2016
Predicting risk factors for varicella zoster virus infection and postherpetic neuralgia after hematopoietic cell transplantation using ordered logistic regression analysisYuko Kanbayashi, Yosuke Matsumoto, Junya Kuroda, et al.
Annals of Hematology|December 4, 2016
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinicAriana Berenson, Suzie Vardanyan, Michael David, et al.
Annals of Hematology|December 25, 2016
Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapyDominik Pretscher, Alexander Kalisch, Martin Wilhelm, et al.
Annals of Hematology|December 25, 2016
Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?Etienne Paubelle, Sophie Ducastelle-Leprêtre, Hélène Labussière-Wallet, et al.
Pageof 667